Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study on the Safety and Effectiveness of Ibrutinib for Children and Young Adults with Chronic Graft Versus Host Disease

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a condition known as Chronic Graft Versus Host Disease (cGVHD), which can occur after a stem cell transplant. The study is investigating the use of a medication called Ibrutinib, which is being tested in different forms such as a suspension for oral use, film-coated tablets, and hard capsules. The purpose of the study is to find the right dose and to assess the safety and effects of Ibrutinib in children and young adults with cGVHD.

The study is divided into two parts. In the first part, researchers aim to determine the appropriate dose of Ibrutinib for children aged 1 to under 12 years. In the second part, the focus is on understanding how the body processes the medication and its safety in participants aged 1 to under 22 years. Participants in the study may have moderate or severe cGVHD that has not responded to previous treatments. Some participants may also be newly diagnosed with cGVHD and require systemic immunosuppression, which is a treatment to reduce the activity of the immune system.

Throughout the study, participants will receive either Ibrutinib or a placebo. The study will monitor the response to the treatment over a period of time, including the duration of response and overall survival rate. Additionally, the study will observe the growth and development of pediatric participants. The trial is expected to continue until November 2025, with the aim of providing valuable information on the use of Ibrutinib in treating cGVHD in younger patients.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the patient will be informed about the trial's purpose and procedures. Consent will be obtained from the patient or their guardian.

  2. Step 2

    Initial assessment

    An initial assessment will be conducted to evaluate the patient's health status and eligibility. This includes reviewing the patient's medical history and current condition related to chronic graft versus host disease (cGVHD).

  3. Step 3

    Medication administration

    The patient will receive Ibrutinib and Prednisone as part of the treatment. Ibrutinib is administered orally in the form of film-coated tablets or capsules. Prednisone is also administered orally in tablet form.

    The dosage and frequency of administration will be determined based on the patient's specific needs and the study's protocol. The treatment duration will be specified by the study guidelines.

  4. Step 4

    Monitoring and follow-up

    Regular monitoring will be conducted to assess the patient's response to the treatment and to ensure safety. This includes checking for any side effects or changes in the patient's condition.

    Follow-up visits will be scheduled to evaluate the effectiveness of the treatment and to make any necessary adjustments.

  5. Step 5

    Completion of the study

    Upon completion of the study, a final assessment will be conducted to evaluate the overall outcomes and any long-term effects of the treatment.

    The patient will be informed about the results and any further steps if needed.

Who can join the trial?

10 criteria

  • Participants must have **moderate or severe chronic Graft Versus Host Disease (cGVHD)**, which means the condition is affecting them significantly.
  • Participants should have tried at least one other treatment for cGVHD that did not work.
  • For Part B, participants can also be newly diagnosed with moderate or severe cGVHD and need treatment that affects the whole body (systemic immunosuppression).
  • Newly diagnosed participants should not have had previous treatments for cGVHD, except for **corticosteroids** (a type of medication) taken within 72 hours before agreeing to join the study.
  • Participants may be taking other medications to prevent or treat a different condition called acute GVHD, but if they are taking **prednisone** (a type of corticosteroid), it must be at a low dose (0.5 mg per kg of body weight per day or less) when they join the study.
  • Participants must have a history of receiving a **stem cell transplant** from another person (allogeneic transplantation).
  • For Part A, participants must be between 1 and less than 12 years old. For Part B, participants must be between 1 and less than 22 years old.
  • Participants or their parents/guardians must provide written consent, which means they agree to join the study after understanding what it involves.
  • Participants or their parents/guardians must understand the purpose and risks of the study and agree to share health information as required by privacy laws.
  • Children who are able to understand should also agree to participate in the study.

Who cannot join the trial?

6 criteria

  • Patients who are not diagnosed with Chronic Graft Versus Host Disease (cGVHD) cannot participate. This is a condition that can occur after a bone marrow or stem cell transplant, where the donated cells attack the recipient's body.
  • Patients who are younger than 1 year old or older than 22 years old are not eligible to join the study.
  • Patients who do not meet the specific health criteria set by the study cannot participate. These criteria are based on guidelines from the National Institutes of Health (NIH).
  • Patients who are not able to safely take the study medication, ibrutinib, due to other health conditions or medications they are taking, will be excluded.
  • Patients who are pregnant or breastfeeding cannot participate in the study.
  • Patients who are unable to follow the study procedures or attend the required visits will not be eligible.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Ibrutinib is a medication being studied for its potential use in children with chronic graft versus host disease (cGVHD). This trial aims to find the right dose for children and to understand how the body processes the medication. The study also looks at the safety of using this medication in young patients.

What is already known about the treatment

Ibrutinib – Ibrutinib is administered orally in the form of capsules or tablets. It is currently being studied in clinical trials for its effectiveness and safety in treating chronic graft versus host disease (cGVHD) in pediatric patients. The medication is primarily used to manage certain types of cancers and immune system disorders. It works by inhibiting a specific protein called Bruton's tyrosine kinase (BTK), which plays a crucial role in the growth and survival of cancer cells. Ibrutinib is classified as a targeted therapy, specifically a BTK inhibitor, and is being evaluated for its potential benefits in younger populations with cGVHD.

Investigated diseases

Chronic Graft Versus Host Disease (cGVHD) – This condition occurs when donor cells attack the recipient's body after a stem cell or bone marrow transplant. It is a long-term complication that can affect various organs, including the skin, liver, and digestive tract. Symptoms may include skin rashes, dry eyes, and mouth, as well as liver dysfunction. The disease can progress slowly, with symptoms appearing months or even years after the transplant. Over time, it can lead to chronic inflammation and fibrosis in affected tissues. The severity and progression of symptoms can vary widely among individuals.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase ITrial ID2023-507330-24-00Protocol codePCYC-1146-IMEstimated enrolment60 patientsSponsorAbbVie Deutschland GmbH & Co. KG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.